If they launch [Copaxone] or not would depend on if MNTA/NVS believes they would win that lawsuit.
What I’m saying is I don’t think NVS/MNTA will launch unless they have already won in the District Court. Launching after winning in the District Court still incurs risk of reversal on appeal, but it’s very much less risky than launching without a win in the District Court.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”